Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib

Br J Haematol. 2020 Jul;190(1):e48-e51. doi: 10.1111/bjh.16709. Epub 2020 May 1.

Authors

Affiliations

¹ Section of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL, USA.
² Department of Medicine, University of Chicago Medicine, Chicago, IL, USA.
³ Department of Pathology, University of Chicago Medicine, Chicago, IL, USA.
⁴ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.

PMID: 32358888
DOI: 10.1111/bjh.16709

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Aminopyridines / therapeutic use*
Female
Humans
Isocitrate Dehydrogenase / genetics*
Male
Middle Aged
Mutation
Myeloproliferative Disorders / drug therapy*
Myeloproliferative Disorders / enzymology
Myeloproliferative Disorders / genetics
Treatment Outcome
Triazines / therapeutic use*

Substances

Aminopyridines
Triazines
enasidenib
IDH2 protein, human
Isocitrate Dehydrogenase